Obesity rates have decreased slightly in the US and while it’s too early to say whether the trend will hold and what’s causing the change, experts believe weight-loss drugs could be playing a role in continuing to lower obesity and reduce related health risks.
These medications – Ozempic, Wegovy, Mounjaro and others – are called GLP-1 agonists, and they were originally developed to treat type 2 diabetes. But they also show great promise for treating obesity and other health conditions, like heart disease, kidney and liver issues, sleep apnea, asthma, Covid complications and cancer, among others.
